CTRI/2015/02/005585招募中2 期
A Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Capsule Menoease in Women with Menopausal Symptoms - MNES
Charak Pharma Pvt Ltd CPP0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria
- •The participant may enter the trial if ALL of the following apply:
- •Participant is willing and able to give informed consent for participation in the trial
- •Female of age : 45 Years to 55 Years with menopausal symptoms
- •Absence of menstrual period for 6 to 12 months but not more than 2 years
- •Participant has clinically acceptable laboratory results
- •In the investigatorâ??s opinion, is able and willing to comply with all trial requirements
排除标准
- •Exclusion Criteria
- •The participant may not enter the trial if ANY of the following apply:
- •Women on HRT or post HRT
- •Treatment with estrogens, progesterone, Raloxifene, or Tamoxifen
- •Use of prescription or over-the-counter medications to treat hot flushes
- •Known history of Hyperthyroidism or Hypothyroidism
- •Clinically suspected benign or malignant lesions in uterus, cervix or vagina
- •Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participantâ??s ability to participate in the trial
- •Participants who have participated in another research trial involving an investigational product in the past 12 weeks
研究者
相似试验
尚未招募
2 期
Efficacy Evaluation of SARVONUTRA M as Male Wellness AgentCTRI/2022/05/042708SARVOTHAM CARE LIMITED
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-NLTheracos Sub, LLC1,650
已完成
3 期
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse eventsType 2 diabetes and increased risk of cardiovascular adverse events100192801001842410003216NL-OMON47856Theracos Sub, LLC132
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861EUCTR2015-001760-19-DKTheracos Sub, LLC1,650
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-PLTheracos Sub, LLC1,650